Viridian Therapeutics, Inc. (LON: 0K1R)
London
· Delayed Price · Currency is GBP · Price in USD
18.28
-0.62 (-3.28%)
Jan 22, 2025, 7:14 PM BST
Viridian Therapeutics Employees
Viridian Therapeutics had 94 employees as of December 30, 2023. The number of employees increased by 8 or 9.30% compared to the previous year.
Employees
94
Change (1Y)
8
Growth (1Y)
9.30%
Revenue / Employee
2.40K GBP
Profits / Employee
-2.04M GBP
Market Cap
1.18B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
ConvaTec Group | 10,136 |
Hikma Pharmaceuticals | 9,100 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Viridian Therapeutics News
- 15 days ago - Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - Business Wire
- 4 weeks ago - Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade) - Seeking Alpha
- 5 weeks ago - Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation - Seeking Alpha
- 5 weeks ago - Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade) - Seeking Alpha
- 5 weeks ago - Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
- 5 weeks ago - Viridian stock soars 25% on Phase 3 data for veligrotug - Seeking Alpha
- 5 weeks ago - Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease - Investor's Business Daily
- 5 weeks ago - Viridian Therapeutics Announces Positive Phase 3 Results for Veligrotug in Treating Thyroid Eye ... - GuruFocus